51336-47-1

Usage

Uses

Used in Pharmaceutical Research and Development:
AKOS B005891 is used as a research compound for understanding the pharmacokinetics and metabolism of cetirizine, a commonly used antihistamine medication. Its study aids in the development of more effective and safer medications for allergy treatment.
Used in Drug Metabolism Studies:
AKOS B005891 is used as a metabolite in drug metabolism studies, providing insights into the metabolic pathways and biotransformation processes of cetirizine in the body. This information is vital for optimizing drug dosages and minimizing potential side effects.
Used in Pharmacokinetics Research:
AKOS B005891 is used as a key component in pharmacokinetics research, helping to determine the absorption, distribution, metabolism, and excretion of cetirizine. This knowledge is crucial for designing effective drug therapies and improving patient outcomes.
Used in Allergy Treatment Development:
AKOS B005891 is used as a reference compound in the development of new allergy treatments. By studying its properties and interactions with the body, researchers can identify potential therapeutic targets and design more effective medications for allergy sufferers.

Upstream product

• 90-02-8 salicylaldehyde 
• 105-36-2 ethyl bromoacetate 
• 1761-61-1 5-bromosalicyclaldehyde 

Downstream Products

• 194163-50-3 ethyl [4-bromo-2-(hydroxymethyl)phenoxy]acetate 
• 24589-89-7 2-(4-bromo-2-formylphenoxy)acetic acid 
• 51336-46-0 2,6-Dimethyl-4-(2-ethoxycarbonylmethoxy-5-bromophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid diethyl ester 
• 10242-11-2 5-bromobenzo[b]furan-2-carboxylic acid 
• 188714-86-5 2-Butyl-5-chloro-3-{5-[2-(1-trityl-1H-tetrazol-5-yl)-phenyl]-benzofuran-2-ylmethyl}-3H-imidazole-4-carbaldehyde 
• 188714-87-6 (2-Butyl-5-chloro-3-{5-[2-(1-trityl-1H-tetrazol-5-yl)-phenyl]-benzofuran-2-ylmethyl}-3H-imidazol-4-yl)-methanol 
• 188714-62-7 5-[2-(1-Trityl-1H-tetrazol-5-yl)-phenyl]-benzofuran-2-carboxylic acid ethyl ester 
• 188714-66-1 5-[2-(3-Bromo-2-bromomethyl-benzofuran-5-yl)-phenyl]-1-trityl-1H-tetrazole 
• 188714-64-9 5-[2-(2-Bromomethyl-benzofuran-5-yl)-phenyl]-1-trityl-1H-tetrazole 
• 188714-63-8 {5-[2-(1-Trityl-1H-tetrazol-5-yl)-phenyl]-benzofuran-2-yl}-methanol 
• 188714-65-0 5-[2-(3-Bromo-2-bromomethyl-benzofuran-5-yl)-phenyl]-1H-tetrazole 
• 13923-56-3 ethyl [4-bromo-2-(chloromethyl)phenoxy]Acetate 

Relevant academic research and scientific papers

Benzofuran-Based Carboxylic Acids as Carbonic Anhydrase Inhibitors and Antiproliferative Agents against Breast Cancer

Pursuing our effort for developing effective inhibitors of the cancer-related hCA IX isoform, here we describe the synthesis of novel benzofuran-based carboxylic acid derivatives, featuring the benzoic (9a-f) or hippuric (11a,b) acid moieties linked to 2-

Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site

A novel series of shikonin-benzo[b]furan derivatives were designed and synthesized as tubulin polymerization inhibitors, and their biological activities were evaluated. Most compounds revealed the comparable anti-proliferation activities against the cancer cell lines to that of shikonin and simultaneously low cytotoxicity to non-cancer cells. Among them, compound 6c displayed powerful anti-cancer activity with the IC50 value of 0.18 μM against HT29 cells, which was significantly better than that of the reference drugs shikonin and CA-4. What's more, 6c could inhibit tubulin polymerization and compete with [3H] colchicine in binding to tubulin. Further biological studies depicted that 6c can induce cell apoptosis and cell mitochondria depolarize, regulate the expression of apoptosis related proteins in HT29 cells. Besides, 6c actuated the HT29 cell cycle arrest at G2/M phase, and influenced the expression of the cell-cycle related protein. Moreover, 6c displayed potent inhibition on cell migration and tube formation that contributes to the antiangiogenesis. These results prompt us to consider 6c as a potential tubulin polymerization inhibitor and is worthy for further study.

Organocatalytic Synthesis of Fused Bicyclic 2,3-Dihydro-1,3,4-oxadiazoles through an Intramolecular Cascade Cyclization

Hydrazone-carboxylic acids undergo intramolecular cyclization in the presence of pivaloyl chloride, iPr2NEt, and catalytic DABCO to form a range of substituted fused tricyclic 2,3-dihydro-1,3,4-oxadiazoles in high yields.

1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS

The present invention relates to 1-phenyl-substituted heterocyclyl derivatives of the formula (I), wherein Y, Z, R1, R2, R3 and R4 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.

AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR

The present invention provides a GPR receptor function regulator comprising the compound represented by the formula: [wherein ring A is an optionally substituted isocyclic or heterocyclic ring, P is a bond or spacer, ring D is an optionally substituted monocyclic aromatic ring which may be condensed with a 5-to 7-membered ring, V is a bond or the group represented by the formula -CR14=CR15 - or - N=CR16- (wherein R14, R15 and R16 each represents a hydrogen atom or optionally substituted hydrocarbon group), Q is a bond or spacer, and W is a carboxyl or a group biologically equivalent to a carboxyl] or its salt or a prodrug thereof

VITAMIN D RECEPTOR MODULATORS

The present invention relates to novel, non-secosteroidal, phenyl-benzofuran compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1α,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES

The present invention is related to azolidinedione-vinyl fused-benzene derivatives of formula (I) for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, graft rejection or lung injuries. Formula (I), wherein A, X, Y, Z, R1 , R2 and n are as described in the description.

Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists

This invention relates to novel benzofuran and dihydrobenzofuran compounds, pharmaceutical compositions containing such compounds, and methods of treating beta-3 adrenoreceptor-mediated conditions with such compositions.

P(MeNCH2CH2)3N: An efficient catalyst for the synthesis of substituted ethyl benzofuran-2-carboxylates

A superior method for the synthesis of substituted ethyl benzofuran-2-carboxylates in 80-99% yields from substituted 2-formylphenoxy ethylcarboxylates using 0.4 equiv of commercially available P(MeNCH2CH2)3N at 70 °C for 3 hours is described.

Aromatic amidine derivatives useful as selective thrombin inhibitors

The present invention relates to a novel thrombin inhibitor which is effective even when orally administered. More specifically, the present invention relates to an aromatic amidine derivative represented by formula (I) and the salts thereof, which show potent selective inhibitory activity for thrombin in which (a), R, R1, R2, R3, A, W, Y and n are defined as described in the specification.